PMID- 31702013
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20210203
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 105
IP  - 3
DP  - 2020 Mar 1
TI  - Long-Term Outcomes of Treatments for Central Precocious Puberty or Early and Fast 
      Puberty in Chinese Girls.
LID - dgz027 [pii]
LID - 10.1210/clinem/dgz027 [doi]
AB  - CONTEXT: Gonadotropin-releasing hormone analogues (GnRHa) and recombinant human 
      growth hormone (rhGH) have been widely used to treat idiopathic central 
      precocious puberty (CPP) or early and fast puberty (EFP). However, large-scale 
      studies to evaluate the treatment effects on final adult height (FAH) are still 
      lacking. OBJECTIVE: To assess the effects of long-term treatment for CPP/EFP on 
      FAH and its main influencing factors. DESIGN AND SETTING: Retrospective, 
      multicenter observational study from 1998 to 2017. PARTICIPANTS: Four hundred 
      forty-eight Chinese girls with CPP/EFP received GnRHa and rhGH treatment (n = 
      118), GnRHa alone (n = 276), or no treatment (n = 54). MAIN OUTCOME MEASURES: 
      FAH, target height (Tht), and predictive adult height (PAH). RESULTS: The height 
      gain (FAH-PAH) was significantly different among the GnRHa and rhGH treatment, 
      GnRHa alone, and no treatment groups (P < 0.05; 9.51 +/- 0.53, 8.07 +/- 0.37, and 
      6.44 +/- 0.91 cm, respectively). The genetic height gain (FAH-Tht) was 4.0 +/- 0.5 cm 
      for the GnRHa + rhGH group and 2.0 +/- 0.27 cm for the GnRHa group, while the 
      control group reached their Tht. In addition, 5 critical parameters derived from 
      PAH, bone age, and Tht, showed excellent performance in predicting which patients 
      could gain >/=5 cm (FAH-PAH), and this was further validated using an independent 
      study. CONCLUSIONS: The overall beneficial effect of GnRHa + rhGH or GnRHa on FAH 
      was significant. The control group also reached their genetic target height. 
      Clinicians are recommended to consider both the potential gains in height and the 
      cost of medication.
CI  - (c) Endocrine Society 2019. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Fu, Junfen
AU  - Fu J
AD  - Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
FAU - Zhang, Jianwei
AU  - Zhang J
AD  - Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
AD  - Shaoxing Women and Children's Hospital, Shaoxing, China.
FAU - Chen, Ruimin
AU  - Chen R
AD  - Fuzhou Children's Hospital of Fujian, Fujian Medical University Teaching 
      Hospital, Fuzhou, China.
FAU - Ma, Xiaoyu
AU  - Ma X
AD  - Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, 
      China.
FAU - Wang, Chunlin
AU  - Wang C
AD  - The First Affiliated Hospital of Zhejiang University School of Medicine, 
      Hangzhou, China.
FAU - Chen, Linqi
AU  - Chen L
AD  - Children's Hospital of Soochow University, Suzhou, China.
FAU - Liang, Yan
AU  - Liang Y
AD  - Tongji Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan, China.
FAU - Luo, Xiaoping
AU  - Luo X
AD  - Tongji Hospital, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan, China.
FAU - Yang, Yu
AU  - Yang Y
AD  - Children's Hospital of Jiangxi Province, Nanchang, China.
FAU - Xiong, Feng
AU  - Xiong F
AD  - Children's Hospital of Chongqing Medical University, Chongqing, China.
FAU - Su, Zhe
AU  - Su Z
AD  - Shenzhen Children's Hospital, Shenzhen, China.
FAU - Wu, Jing
AU  - Wu J
AD  - Lishui City People's Hospital, Lishui, China.
FAU - Yao, Hui
AU  - Yao H
AD  - Wuhan Children's Hospital, Wuhan, China.
FAU - Xu, Jinliang
AU  - Xu J
AD  - Shaoxing Women and Children's Hospital, Shaoxing, China.
FAU - Wu, Di
AU  - Wu D
AD  - Beijing Children's Hospital, Capital Medical University, Beijing, China.
FAU - Ni, Yan
AU  - Ni Y
AD  - Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 12629-01-5 (Human Growth Hormone)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
SB  - IM
CIN - J Clin Endocrinol Metab. 2020 Oct 1;105(10):. PMID: 32770225
CIN - J Clin Endocrinol Metab. 2020 Oct 1;105(10):. PMID: 32770230
MH  - Adolescent
MH  - Body Height/*drug effects
MH  - Bone Development/*drug effects
MH  - Child
MH  - China/epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Gonadotropin-Releasing Hormone/*analogs & derivatives
MH  - Human Growth Hormone/*administration & dosage
MH  - Humans
MH  - Male
MH  - Puberty, Precocious/*drug therapy/epidemiology
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2019/11/09 06:00
MHDA- 2020/11/11 06:00
CRDT- 2019/11/09 06:00
PHST- 2019/02/08 00:00 [received]
PHST- 2019/10/04 00:00 [accepted]
PHST- 2019/11/09 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2019/11/09 06:00 [entrez]
AID - 5614782 [pii]
AID - 10.1210/clinem/dgz027 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz027. doi: 10.1210/clinem/dgz027.